Cargando…
Novel therapeutic targets and agents for pediatric dyslipidemia
Landmark studies have convincingly demonstrated that atherosclerosis begins in youth. While generally asymptomatic, an increasing number of youth with disorders of lipid and lipoprotein metabolism, such as familial hypercholesterolemia, are being identified through selective and universal screening....
Autores principales: | Sunil, Bhuvana, Foster, Christy, Wilson, Don P., Ashraf, Ambika P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637781/ https://www.ncbi.nlm.nih.gov/pubmed/34868544 http://dx.doi.org/10.1177/20420188211058323 |
Ejemplares similares
-
Dyslipidemia in Pediatric Type 2 Diabetes Mellitus
por: Sunil, Bhuvana, et al.
Publicado: (2020) -
Osteopetrorickets Presenting with Failure to Thrive and Hypophosphatemia
por: Freese, Jurhee, et al.
Publicado: (2020) -
Glycaemic control and outcomes in children with type 2 diabetes diagnosed at or before 10 years of age
por: Greenup, Erin, et al.
Publicado: (2020) -
Case report: 11-ketotestosterone may potentiate advanced bone age as seen in some cases of Wiedemann-Steiner Syndrome
por: Buchanan, Katherine, et al.
Publicado: (2022) -
Cholesterol: The Good, the Bad, and the Ugly – Therapeutic Targets for the Treatment of Dyslipidemia
por: Elshourbagy, Nabil A., et al.
Publicado: (2014)